Abstracts tagged "gout"

Abstract Number: 1218 • 2014 ACR/ARHP Annual Meeting
The Reduction of Serum Uric Acid Level Might Prevent Atherosclerosis in Mice
Yoshitaka Kimura^1,2, Tamiko Yanagida³, Akiko Onda⁴, Hajime Kono², Maki Takayama², Kurumi Asako², Akiko Okamoto², Hirotoshi Kikuchi² and Toshihiro Nanki⁵, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ³Depart ment of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ⁴Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ⁵Department of Clinical Research Medicine, Teikyo University, Tokyo, Japan
Background/Purpose: Excess amount of uric acid in human body causes acute inflammation, gout. In addition, uric acid is identified as a danger signal and is…
Abstract Number: 152 • 2014 ACR/ARHP Annual Meeting
Subclinical Synovial Inflammation in Gout
Priya Chowalloor^1,2, Patrick Cheah³ and Helen I. Keen^1,2, ¹Rheumatology, Royal Perth Hospital, Perth, Australia, ²School of Medicine and Pharmacology, The University of Western Australia, Crawley, Australia, ³Rheumatology, Sir Charles Gairdner Hospital, Nedlands, Australia
Background/Purpose Gout is poorly managed in the community. Long standing poorly controlled gout can lead into progressive destructive arthropathy, decreased quality of life and increased…
Abstract Number: 1165 • 2014 ACR/ARHP Annual Meeting
Evaluation of Symptom Control Among Treated Gout Patients in the United States, United Kingdom, and Germany
Robert Morlock¹, Chris Storgard², Vernon F. Schabert³, Augustina Ogbonnaya³, Pierre Chevalier⁴, Dionne Hines³ and Sulabha Ramachandran⁵, ¹4939 Directors Place, Ardea Biosciences, San Diego, CA, ²Ardea Biosciences, Inc., San Diego, CA, ³IMS Health, Alexandria, VA, ⁴IMS Health, Vilvoorde, Belgium, ⁵AstraZeneca, Wilmington, DE
Background/Purpose: Gout affects approximately 1-4% of the population in developed Western countries. The hallmark signs of gout are elevated serum uric acid (SUA) level, episodes…
Abstract Number: 105 • 2014 ACR/ARHP Annual Meeting
Resource Use and Health Related Quality of Life Burden of Gout Exacerbated By Common Comorbidities: Results from the 2012-2013 National Health and Wellness Survey
Robert Morlock¹, Natalia M. Flores², Kathy Annunziata³, J. Chapnick⁴ and Sulabha Ramachandran⁵, ¹4939 Directors Place, Ardea Biosciences, San Diego, CA, ²Kantar Health, Foster City, CA, ³Kantar Health, Princeton, NJ, ⁴Kantar Health, Horsham, PA, ⁵AstraZeneca, Wilmington, DE
Background/Purpose: Gout is caused by chronic high serum uric acid (SUA) levels (i.e., hyperuricemia), which leads to the deposition of monosodium urate crystals in musculoskeletal…
Abstract Number: 888 • 2014 ACR/ARHP Annual Meeting
Annual Medical Care Expenditures Among US Adults with Gout, 2005 – 2011
Miriam G. Cisternas¹, Louise Murphy², David J. Pasta³, Edward H. Yelin⁴ and Charles Helmick⁵, ¹MGC Data Services, Carlsbad, CA, ²Division of Population Health, Centers for Disease Control and Prevention, Atlanta, GA, ³DMA Corporation, Palo Alto, CA, ⁴Arthritis Research Group, University of California, San Francisco, San Francisco, CA, ⁵Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: Costs associated with gout are of growing interest due to its increasing prevalence, but quantifying those costs has been hampered by its co-occurrence with…
Abstract Number: 827 • 2014 ACR/ARHP Annual Meeting
Gout and the Risk of Alzheimer’s Disease: A Population-Based Cohort Study
Na Lu¹, Yuqing Zhang¹, Alberto Ascherio², Miguel Hernan², Tuhina Neogi¹, Maureen Dubreuil^3,4 and Hyon K. Choi⁵, ¹Boston University School of Medicine, Boston, MA, ²Epidemiology, Harvard School of Public Health, Boston, MA, ³Rheumatology, Boston University Medical Center, Boston, MA, ⁴Rheumatology, Boston VA HealthCare System, Boston, MA, ⁵Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: While gout is associated with cardiovascular (CV)-metabolic comorbidities and their sequelae, uric acid's anti-oxidant effects may have neuroprotective benefits. Several studies have found an…
Abstract Number: 250 • 2014 ACR/ARHP Annual Meeting
Early Gout Pain Response at 28 Hours Predicts Response at 5 Days on Both Patient Pain and Physician Global Assessment
Paul M. Peloso¹, Ted R. Mikuls², Brian W. Coburn³, H. Ralph Schumacher Jr.⁴, Davis F. Gates¹, Zoran Popmihajlov¹, Walter L. Straus¹ and R. Andrew Moore⁵, ¹Merck & Co., Inc., Whitehouse Station, NJ, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³Omaha VA and University of Nebraska Medical Center, Omaha, NE, USA, Omaha, NE, ⁴Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁵University of Oxford, Nuffield Division of Anaesthetics, Oxford, England
Background/Purpose This post-hoc analysis from a randomized trial1in acute gout asked whether early pain responses predict subsequent pain and investigator global responses. Methods Patient assessment…
Abstract Number: 180 • 2014 ACR/ARHP Annual Meeting
Analytical Comparison Between Point of Care Uric Acid Testing Meters
Jonathan Paraskos¹, Zsofia Berke², Jason Cook¹, Jeffrey N. Miner³, Martin Braddock¹, Adam Platt¹ and Glen Hughes¹, ¹AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ²R&D, AstraZeneca, Mölndal, Sweden, ³Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Gout is a chronic, painful, debilitating form of arthritis resulting from elevated levels of serum uric acid (SUA), termed hyperuricemia. Hyperuricemia is caused by…
Abstract Number: 171 • 2014 ACR/ARHP Annual Meeting
High-Protein Diet (Atkins Diet) and Uric Acid Response
Na Lu¹, Iris Shai², Yuqing Zhang¹, Gary Curhan³ and Hyon K. Choi⁴, ¹Boston University School of Medicine, Boston, MA, ²Harvard School of Public Health, Boston, MA, ³German Research Center for Environmental Health, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose The conventional low-purine dietary approach to gout offers limited efficacy, palatability, and sustainability, and promotes increased consumption of refined carbohydrates and saturated fat that…
Abstract Number: 169 • 2014 ACR/ARHP Annual Meeting
Is Gout a Coronary Heart Disease Risk Equivalent, Similar to Diabetes?
Jasvinder A. Singh¹, Rekha Ramachandaran², Jie Zhang³, Fenglong Xie⁴, Shuo Yang⁵, Huifeng Yun⁶ and Jeffrey R. Curtis², ¹Department of Medicine, University of Alabama, Tuscaloosa, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Ryals Soph Bldg., Rm. 517b, Univ. of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁵Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL
Background/Purpose: Diabetes is a well-recognized risk factor for heart disease, increasing the risk of heart disease by 2-3 fold in many studies. Recent ACC/AHA lipid…
Abstract Number: 2962 • 2014 ACR/ARHP Annual Meeting
Association of the Toll-like Receptor 4 (TLR4) Gene with Gout
Humaira Rasheed¹, Ruth Topless¹, Richard Day², Diluk Kannangara³, Kenneth Williams³, Linda Bradbury⁴, Matthew Brown⁵, Catherine Hill⁶, Susan Lester⁷, Maureen Rischmueller⁸, Malcolm Smith⁹, Mariano Andrés¹⁰, Thomas Bardin¹¹, Michael Doherty¹², Matthijs Janssen¹³, Tim Jansen¹⁴, Leo Joosten¹⁵, Fernando Perez-Ruiz¹⁶, Timothy Radstake¹⁷, Philip L. Riches¹⁸, Ed Roddy¹⁹, Anne-Kathrin Tausche²⁰, Lisa K. Stamp²¹, Nicola Dalbeth²², Frederic Lioté²³, Alex So²⁴, Cushla McKinney¹ and Tony R. Merriman¹, ¹Department of Biochemistry, University of Otago, Dunedin, New Zealand, ²Dept of Clin Pharmacology, St. Vincent's Hospital, Sydney, Australia, ³University of New South Wales, Sydney, Australia, ⁴The University of Queensland, Brisbane, Australia, ⁵University of Queensland Diamantina Institute, Brisbane, Australia, ⁶Queen Elizabeth Hospital, Adelaide, Australia, ⁷Rheumatology Unit, Queen Elizabeth Hospital, Woodville South, Australia, ⁸Department of Rheumatology, The Queen Elizabeth Hospital, SA, Australia, ⁹Rheumatology Unit Repatriation, Queen Elizabeth Hospital, Adelaide, Australia, ¹⁰Rheumatology Section, Hospital General Universitario de Alicante, Alicante, Spain, ¹¹Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France, ¹²Academic Rheumatology, City Hospital, Nottingham, United Kingdom, ¹³Department of Rheumatology, Rijnstate Hospital, Arnhem, Netherlands, ¹⁴Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ¹⁵Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, ¹⁶Servicio de Reumatologia, Hospital De Cruces, Baracaldo, Spain, ¹⁷University Medical Center Utrecht, Utrecht, Netherlands, ¹⁸Centre for Rheumatic Diseases, University of Edinburgh, Edinburgh, United Kingdom, ¹⁹Research Institute for Primary Care and Health Sciences, Keele University, Staffordshire, United Kingdom, ²⁰Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, ²¹University of Otago, Christchurch, New Zealand, ²²Department of Medicine, University of Auckland, Auckland, New Zealand, ²³UFR médicale, Université Paris Diderot, Paris, France, ²⁴Service De Rhumatologie, CHUV, Lausanne, Switzerland
Background/Purpose: Gout results from innate immune response to monosodium urate (MSU) crystals that form in the context of supersaturation of urate. Identification of genetic risk…
Abstract Number: 167 • 2014 ACR/ARHP Annual Meeting
Target Serum Urate: Do Patients Know Their Goal?
Brian W. Coburn¹, Kayli A. Bendlin², Harlan Sayles¹, Kathryn S. Hentzen³, Michaela M. Hrdy³ and Ted R. Mikuls¹, ¹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ²Pharmacy, Omaha VA Medical Center, Omaha, NE, ³Omaha VA Medical Center, Omaha, NE
Background/Purpose: Treat-to-target approaches are used to achieve therapeutic goals in conditions such as diabetes and rheumatoid arthritis. This strategy has also been widely endorsed in…
Abstract Number: 2963 • 2014 ACR/ARHP Annual Meeting
The URAT1 Uric Acid Transporter Is Important in Uric Acid Homeostasis and Its Activity May be Altered in Gout Patients and in Drug-Induced Hyperuricemia
Philip K. Tan, Sha Liu and Jeffrey N. Miner, Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Gout results from chronic hyperuricemia. Most gout patients exhibit an increased renal reabsorption of uric acid which leads to elevated levels of serum uric…
Abstract Number: 166 • 2014 ACR/ARHP Annual Meeting
Risk Factors for Gout Attack Recurrence during Urate-Lowering Allopurinol Treatment
Myeong Jae Yoon¹, Ji Ae Yang², Sang Hyun Joo¹, Sang Jin Lee¹, Jin Young Moon¹, Hyun Mi Kwon¹, Dong Jin Ko¹, Yeong Wook Song¹ and Eun Bong Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
Background/Purpose Gout is a recurrent inflammatory arthritis caused by crystal deposition of monosodium urate, which can be prevented urate-lowering agents such as allopurinol. However, gout…
Abstract Number: 2176 • 2014 ACR/ARHP Annual Meeting
Macrophages-Mediated Response to Uric Acid Crystals Is Modulated By Their Functional Polarization
Emma Garcia-Melchor¹, Monica Guma², Jordi Yagüe¹, Manel Juan¹ and Jacquie Harper³, ¹Immunology Department, Hospital Clinic Barcelona, Barcelona, Spain, ²Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ³Arthritis and Inflammation Group, Malaghan Institute of Medical Research, Wellington, New Zealand
Background/Purpose: Macrophages have been involved in both initiation and resolution of gout flares. Accordingly, these cells are characterized by their plasticity as the environment modulates…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].